Ajit Ramalingam - 01 Sep 2023 Form 4 Insider Report for BIO-RAD LABORATORIES, INC. (BIO)

Reporting relationship: SVP, Chief Accounting Officer
Issuer ticker: BIO
Reported as of: 01 Sep 2023
Net transaction value: -$80,104
SEC form: 4
Accepted by SEC: 06 Sep 2023, 13:04:25 UTC
Prior SEC filing: 07 Jun 2023
Source filing: View source filing
Reporting owner signature: /s/ Ajit Ramalingam

Filing notes and source

Key filing fact

Ajit Ramalingam filed Form 4 for BIO-RAD LABORATORIES, INC. (BIO) on 06 Sep 2023.

Key facts

This page summarizes Ajit Ramalingam's Form 4 filing for BIO-RAD LABORATORIES, INC. (BIO).
9 reported transactions and 3 derivative rows are listed below.
Accepted by SEC: 06 Sep 2023, 13:04.

Change

Previous filing in this sequence was filed on 07 Jun 2023.
Current net transaction value: -$80,104.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

BIO transaction

Bio-Rad A Common Stock

Options Exercise

Transaction value: $0
Shares: +173
Change %: +739%
Price: $0.000000
Shares after: 196
Date: 01 Sep 2023
Ownership: Direct
Footnotes: F1, F2

BIO transaction

Bio-Rad A Common Stock

Tax liability

Transaction value: $23,676
Shares: -60
Change %: -31%
Price: $394.60
Shares after: 136
Date: 01 Sep 2023
Ownership: Direct

BIO transaction

Bio-Rad A Common Stock

Options Exercise

Transaction value: $0
Shares: +169
Change %: +124%
Price: $0.000000
Shares after: 305
Date: 01 Sep 2023
Ownership: Direct
Footnotes: F1

BIO transaction

Bio-Rad A Common Stock

Tax liability

Transaction value: $23,281
Shares: -59
Change %: -19%
Price: $394.60
Shares after: 246
Date: 01 Sep 2023
Ownership: Direct

BIO transaction

Bio-Rad A Common Stock

Options Exercise

Transaction value: $0
Shares: +241
Change %: +98%
Price: $0.000000
Shares after: 487
Date: 02 Sep 2023
Ownership: Direct
Footnotes: F1

BIO transaction

Bio-Rad A Common Stock

Tax liability

Transaction value: $33,146
Shares: -84
Change %: -17%
Price: $394.60
Shares after: 403
Date: 02 Sep 2023
Ownership: Direct

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

BIO transaction Derivative

Restricted Stock Units

Options Exercise

Transaction value: $0
Shares: -173
Change %: -25%
Price: $0.000000
Shares after: 521
Date: 01 Sep 2023
Ownership: Direct
Underlying class: Bio-Rad A Common Stock
Underlying amount: 173
Exercise price: $0.000000
Footnotes: F3, F4

BIO transaction Derivative

Restricted Stock Units

Options Exercise

Transaction value: $0
Shares: -169
Change %: -33%
Price: $0.000000
Shares after: 338
Date: 01 Sep 2023
Ownership: Direct
Underlying class: Bio-Rad A Common Stock
Underlying amount: 169
Exercise price: $0.000000
Footnotes: F3, F5

BIO transaction Derivative

Restricted Stock Units

Options Exercise

Transaction value: $0
Shares: -241
Change %: -50%
Price: $0.000000
Shares after: 241
Date: 02 Sep 2023
Ownership: Direct
Underlying class: Bio-Rad A Common Stock
Underlying amount: 241
Exercise price: $0.000000
Footnotes: F3, F6

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 6 footnotes

Footnote F1

Shares of Class A common stock acquired on the vesting of restricted stock units.

Footnote F2

Includes 23.3950 shares acquired under the Bio-Rad Employee Stock Purchase Plan on 06/30/2023.

Footnote F3

Each restricted stock unit represents a contingent right to receive one share of Bio-Rad Class A common stock.

Footnote F4

On September 1, 2022, the reporting person was granted 694 restricted stock units, vesting in four equal annual installments beginning on the first anniversary of the grant date.

Footnote F5

On September 1, 2021, the reporting person was granted 676 restricted stock units, vesting in four equal annual installments beginning on the first anniversary of the grant date.

Footnote F6

On September 2, 2020, the reporting person was granted 963 restricted stock units, vesting in four equal annual installments beginning on the first anniversary of the grant date.